521 related articles for article (PubMed ID: 26801070)
21. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA
Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381
[TBL] [Abstract][Full Text] [Related]
22. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
Hinrichs JW; van Blokland WT; Moons MJ; Radersma RD; Radersma-van Loon JH; de Voijs CM; Rappel SB; Koudijs MJ; Besselink NJ; Willems SM; de Weger RA
Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
[TBL] [Abstract][Full Text] [Related]
23. High-throughput detection of clinically targetable alterations using next-generation sequencing.
Vendrell JA; Grand D; Rouquette I; Costes V; Icher S; Selves J; Larrieux M; Barbe A; Brousset P; Solassol J
Oncotarget; 2017 Jun; 8(25):40345-40358. PubMed ID: 28404952
[TBL] [Abstract][Full Text] [Related]
24. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
[TBL] [Abstract][Full Text] [Related]
25. Development and Validation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Variants for the Clinical Laboratory.
Strom CM; Rivera S; Elzinga C; Angeloni T; Rosenthal SH; Goos-Root D; Siaw M; Platt J; Braastadt C; Cheng L; Ross D; Sun W
PLoS One; 2015; 10(8):e0136419. PubMed ID: 26295337
[TBL] [Abstract][Full Text] [Related]
26. Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue.
Fassunke J; Haller F; Hebele S; Moskalev EA; Penzel R; Pfarr N; Merkelbach-Bruse S; Endris V
Int J Mol Med; 2015 Nov; 36(5):1233-43. PubMed ID: 26352389
[TBL] [Abstract][Full Text] [Related]
27. Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment.
Cernomaz AT; Macovei II; Pavel I; Grigoriu C; Marinca M; Baty F; Peter S; Zonda R; Brutsche M; Grigoriu B
BMC Pulm Med; 2016 May; 16(1):88. PubMed ID: 27215400
[TBL] [Abstract][Full Text] [Related]
28. Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making.
De Paoli-Iseppi R; Johansson PA; Menzies AM; Dias KR; Pupo GM; Kakavand H; Wilmott JS; Mann GJ; Hayward NK; Dinger ME; Long GV; Scolyer RA
Pathology; 2016 Apr; 48(3):261-6. PubMed ID: 27020503
[TBL] [Abstract][Full Text] [Related]
29. Bioinformatics Basics for High-Throughput Hybridization-Based Targeted DNA Sequencing from FFPE-Derived Tumor Specimens: From Reads to Variants.
Sun S; Murray SS
Methods Mol Biol; 2019; 1908():37-48. PubMed ID: 30649719
[TBL] [Abstract][Full Text] [Related]
30. Technical Validation of a Next-Generation Sequencing Assay for Detecting Actionable Mutations in Patients with Gastrointestinal Cancer.
Wang SR; Malik S; Tan IB; Chan YS; Hoi Q; Ow JL; He CZ; Ching CE; Poh DYS; Seah HM; Cheung KHT; Perumal D; Devasia AG; Pan L; Ang S; Lee SE; Ten R; Chua C; Tan DSW; Qu JZZ; Bylstra YM; Lim L; Lezhava A; Ng PC; Wong CW; Lim T; Tan P
J Mol Diagn; 2016 May; 18(3):416-424. PubMed ID: 26970585
[TBL] [Abstract][Full Text] [Related]
31. Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing.
Wang M; Escudero-Ibarz L; Moody S; Zeng N; Clipson A; Huang Y; Xue X; Grigoropoulos NF; Barrans S; Worrillow L; Forshew T; Su J; Firth A; Martin H; Jack A; Brugger K; Du MQ
J Mol Diagn; 2015 Sep; 17(5):521-32. PubMed ID: 26165823
[TBL] [Abstract][Full Text] [Related]
32. Somatic mutation analysis in melanoma using targeted next generation sequencing.
Miraflor AP; de Abreu FB; Peterson JD; Turner SA; Amos CI; Tsongalis GJ; Yan S
Exp Mol Pathol; 2017 Oct; 103(2):172-177. PubMed ID: 28822769
[TBL] [Abstract][Full Text] [Related]
33. Validation of an NGS mutation detection panel for melanoma.
Reiman A; Kikuchi H; Scocchia D; Smith P; Tsang YW; Snead D; Cree IA
BMC Cancer; 2017 Feb; 17(1):150. PubMed ID: 28228113
[TBL] [Abstract][Full Text] [Related]
34. Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
Deeb KK; Hohman CM; Risch NF; Metzger DJ; Starostik P
Arch Pathol Lab Med; 2015 Jul; 139(7):913-21. PubMed ID: 26125431
[TBL] [Abstract][Full Text] [Related]
35. EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).
Reynolds JP; Tubbs RR; Minca EC; MacNamara S; Almeida FA; Ma PC; Pennell NA; Cicenia JC
Lung Cancer; 2014 Nov; 86(2):158-63. PubMed ID: 25263855
[TBL] [Abstract][Full Text] [Related]
36. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
[TBL] [Abstract][Full Text] [Related]
37. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.
Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ
Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261
[TBL] [Abstract][Full Text] [Related]
38. Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
Velizheva NP; Rechsteiner MP; Wong CE; Zhong Q; Rössle M; Bode B; Moch H; Soltermann A; Wild PJ; Tischler V
Cancer Cytopathol; 2017 Jan; 125(1):30-40. PubMed ID: 27636102
[TBL] [Abstract][Full Text] [Related]
39. Microfluidics-based EGFR mutation detection and its implication in the resource-limited clinical setting.
Joshi P; Gogte P; Pai T; Gurav M; Dhanawade D; Karnik N; Deshpande G; Kaushal R; Shetty O
Int J Exp Pathol; 2024 Jun; 105(3):90-99. PubMed ID: 38717047
[TBL] [Abstract][Full Text] [Related]
40. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
